San Diego-based Proacta has garnered $35 million in its second round of venture capital. Much of that money will be used to develop PR-104, a compound that is designed to kill cancer cells. "PR-104 has the potential to be less toxic and more potent than current therapies. In addition, PR-104 in combination with current chemotherapy and biologic regimens offers the promise of improving current cancer treatments." Clarus Ventures led the round. Release